BioSpace News Archive

Novaliq, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics based on the unique EyeSol® water-free technology, today announced key results of the second pivotal Phase 3 trial (ESSENCE-2) evaluating the investigational drug CyclASol® for the treatment of dry eye disease (DED).

PerkinElmer, Inc. today announced that the Company will present virtually at the annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022 at 11:15 a.m. ET.

NanoVibronix Inc., (NASDAQ: NAOV), a medical device company that produces the UroShield® and PainShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today announced that it has commenced sales in Europe with the signing of a distribution agreement with Medina Healthcare Ltd (“Medina”) in Malta.

EVERSANA today announced it has completed its acquisition of Intouch Group®, a full-service global agency network serving the pharmaceutical industry.

Emmes, a global, full-service Clinical Research Organization dedicated to supporting the advancement of public health and biopharmaceutical innovation and a portfolio company of Behrman Capital, announced that it has acquired Institut Dr. Schauerte, a CRO headquartered in Munich, Germany.

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), today announced that its collaboration partner, Kissei Pharmaceutical Co., Ltd. (“Kissei”), has released positive topline results from its Phase 3 clinical trial in Japan evaluating fostamatinib disodium hexahydrate for the treatment of adult chronic immune thrombocytopenia (ITP).

Arena Pharmaceuticals, Inc. announced that the Compensation Committee of its Board of Directors granted to 16 new employees 28,659 inducement restricted stock units.

AXIM Biotechnologies, Inc (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting COVID-19 diagnostics, oncological research, and dry eye disease, announced today that the Centers for Disease Control and Prevention (CDC) highlighted a study that the Company sponsored on neutralizing antibodies in its recent COVID-19 Science Update: Edition 116.

BioSig Technologies, Inc., a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, announced that it appointed Access Strategy Partners, Inc. to advise on the next phase of the commercial roll-out.

Global health service company Cigna Corporation (NYSE:CI) announced today that David Cordani, president and chief executive officer, will present at the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022 through a virtual webcast.